Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOCRYST PHARMACEUTICALS, INC.

(BCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioCryst Pharmaceuticals, Inc. Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold as Chief Medical Officer

09/14/2022 | 04:01pm EST

BioCryst Pharmaceuticals, Inc. announced that Dr. Bill Sheridan will become chief development officer and will focus on advancing the company's significant pipeline of development candidates. Dr. Ryan Arnold has been appointed as the company's new chief medical officer. Dr. Arnold joins Dr. Sheridan and Dr. Helen Thackray, the company's chief research and development officer, as physicians on the company's leadership team.

Dr. Sheridan joined BioCryst from Amgen in July 2008 as chief medical officer. During his 15-year tenure at Amgen, Dr. Sheridan led the company's medical affairs functions in the U.S. and Europe, making significant contributions to the successful launch of many compounds, including Aranesp®, Enbrel®, Kineret®, Neulasta®, and Sensipar®. He organized the global health economics and outcomes research function, supervised product development team leaders and led several clinical development phase product development teams. Dr. Sheridan earned his MB BS degree (MD equivalent) at the University of Melbourne in Victoria, Australia.

He is a board-certified Fellow of the Royal Australasian College of Physicians, with a subspecialty in medical oncology, and a Fellow of the American College of Physicians. Dr. Arnold joined BioCryst in March 2022 as senior vice president of global medical affairs. He has more than 20 years of industry experience, including prior roles with increasing levels of responsibility in the medical affairs function at multiple companies, including Amgen (where he worked on Dr. Sheridan's team), Genzyme, Biogen, Sage Therapeutics and Annexon Biosciences.

Throughout his career, Dr. Arnold has helped build and lead medical functions, including support for the development and launch of multiple products in specialty and rare disease indications across neurology, hematology, immunology, oncology and other specialty areas. He has a doctorate of osteopathic medicine from the Michigan State University College of Osteopathic Medicine and completed residency training including clinical responsibilities in otolaryngology and facial plastic surgery.


ę S&P Capital IQ 2022
All news about BIOCRYST PHARMACEUTICALS, INC.
11/11BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction..
AQ
11/10Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction..
CI
11/09BioCryst to Present at Upcoming Investor Conferences
AQ
11/07BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635
AQ
11/04BIOCRYST PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
11/04BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/02Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Pric..
MT
11/02RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, ..
MT
11/01BioCryst Pharmaceuticals Q3 Loss Narrows as Revenue Grows
MT
More news
Analyst Recommendations on BIOCRYST PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 267 M - -
Net income 2022 -212 M - -
Net cash 2022 54,9 M - -
P/E ratio 2022 -10,9x
Yield 2022 -
Capitalization 2 289 M 2 289 M -
EV / Sales 2022 8,36x
EV / Sales 2023 6,68x
Nbr of Employees 358
Free-Float 99,0%
Chart BIOCRYST PHARMACEUTICALS, INC.
Duration : Period :
BioCryst Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCRYST PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 12,28 $
Average target price 17,60 $
Spread / Average Target 43,3%
EPS Revisions
Managers and Directors
Jon P. Stonehouse Chief Executive Officer & Director
Michael L. Jones Executive Director-Finance
Anthony Doyle Chief Financial Officer
Robert Alexander Ingram Chairman
Helen M. Thackray Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
BIOCRYST PHARMACEUTICALS, INC.-11.34%2 289
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.44%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930